Richards, Merrill & Peterson, Inc. Puma Biotechnology, Inc. Transaction History
Richards, Merrill & Peterson, Inc.
- $191 Billion
- Q4 2024
A detailed history of Richards, Merrill & Peterson, Inc. transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Richards, Merrill & Peterson, Inc. holds 40 shares of PBYI stock, worth $114. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40Holding current value
$114% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PBYI
# of Institutions
110Shares Held
28.3MCall Options Held
27.9KPut Options Held
3.4K-
Vanguard Group Inc Valley Forge, PA3.64MShares$10.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$10.2 Million0.0% of portfolio
-
Acorn Capital Advisors, LLC New York, NY2.45MShares$7.01 Million6.49% of portfolio
-
Acadian Asset Management LLC Boston, MA1.97MShares$5.64 Million0.02% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.89MShares$5.42 Million0.0% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $130M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...